0
Clinical Investigations: SARCOID |

Early Treatment of Stage II Sarcoidosis Improves 5-Year Pulmonary Function*

Anne Pietinalho, MD, PhD; Pentti Tukiainen, MD, PhD, FCCP; Tari Haahtela, MD, PhD; Tore Persson, PhD; Olof Selroos, MD, PhD, FCCP; the Finnish Pulmonary Sarcoidosis StudyGroup
Author and Funding Information

Affiliations: *From Meltola Hospital (Drs. Pietinalho and Selroos), Karjaa, Finland; the Departments of Pulmonary Medicine (Dr. Tukiainen) and Allergic Diseases (Dr. Haahtela), University Central Hospital, Helsinki, Finland; and AstraZeneca R&D (Drs. Persson and Selroos), Lund, Sweden. ,  A complete list of the members of the Finnish Sarcoidosis Study groupis given in the Appendix.

Correspondence to: Olof Selroos, MD, FCCP, AstraZeneca R&D, S-221 87 Lund, Sweden; e-mail: olof.selroos@astrazeneca.com


Affiliations: *From Meltola Hospital (Drs. Pietinalho and Selroos), Karjaa, Finland; the Departments of Pulmonary Medicine (Dr. Tukiainen) and Allergic Diseases (Dr. Haahtela), University Central Hospital, Helsinki, Finland; and AstraZeneca R&D (Drs. Persson and Selroos), Lund, Sweden. ,  A complete list of the members of the Finnish Sarcoidosis Study groupis given in the Appendix.


Chest. 2002;121(1):24-31. doi:10.1378/chest.121.1.24
Text Size: A A A
Published online

Study objective: To evaluate the 5-year prognosis ofpatients with stage I and stage II newly detected (< 3 months)pulmonary sarcoidosis treated immediately after diagnosis withprednisolone for 3 months followed by inhaled budesonide for 15months.

Design: Randomized, double-blind,placebo-controlled, parallel-group study for 18 months. Thereafter,open follow-up without treatment.

Setting: Twentypulmonary medicine departments in Finland.

Patients:One hundred eighty-nine adult patients, most of them with normal lungfunction, were randomized to treatment. One hundred forty-nine patientswere followed up for 5 years: 79 patients with initial stage I diseaseand 70 patients with stage II disease.

Treatment: Oralprednisolone for 3 months followed by inhaled budesonide for 15 months(800 μg bid), or placebo tablets followed by placebo inhaler therapy.Thereafter, treatment only on an individual basis in the case ofclinical deterioration.

Measurements: Yearly follow-upvisits with chest radiographs, lung function tests (FEV1,FVC), diffusion capacity of the lung for carbon monoxide(Dlco), serum angiotensin-converting enzyme (SACE), andserum and urinary calcium measurements.

Results: Noinitial differences were observed in chest radiographic findingsbetween the active-treatment and placebo-treatment groups, either inpatients with initial stage I or stage II(-III) disease. However, afterthe 5-year follow-up, 18 steroid-treated patients (26%) and 30placebo-treated patients (38%) still had remaining chest radiographicchanges. Placebo-treated patients more frequently required treatmentwith corticosteroids during the 5-year follow-up (p < 0.05).Steroid-treated patients with initial stage II(-III) disease improvedmore in FVC and Dlco (p < 0.05). No differences inreported adverse events or in SACE, serum calcium, or urinary calciumvalues were seen.

Conclusion: Immediate treatment ofpulmonary stage II(-III) sarcoidosis—but not stage I disease—improvedthe 5-year prognosis with regard to lung functionvariables.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543